First patients to receive experimental cancer drug in new combination trial
NCT ID NCT06960395
Summary
This is the first human study of a new experimental drug called VIR-5525 for people with advanced solid tumors that have spread or cannot be removed by surgery. Researchers will test VIR-5525 alone and combined with an existing immunotherapy drug (pembrolizumab) in 450 participants to find safe doses and see if it shows early signs of shrinking tumors. The study focuses on cancers known to have a specific protein marker called EGFR.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health Research Institute
RECRUITINGScottsdale, Arizona, 85258-4566, United States
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
-
Princess Alexandra Hospital
NOT_YET_RECRUITINGWoolloongabba, Queensland, 4102, Australia
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Conditions
Explore the condition pages connected to this study.